MedTrace Logo

CAR-37 T Cells in Hematologic Malignancies

NCT04136275 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-12-12

No results posted yet for this study

Summary

This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells.

\- Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment

Conditions

  • Hematologic Malignancy
  • Leukemia
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
  • Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL

CAR-37 T cells

CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells

Sponsors & Collaborators

  • Marcela V. Maus, M.D.,Ph.D.

    lead OTHER

Principal Investigators

  • Matthew J. Frigault, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-19
Primary Completion
2023-09-30
Completion
2024-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136275 on ClinicalTrials.gov